vaccine, varicella-zoster




Agencia Lei Va Hong
Concise Prescribing Info
Live attenuated Oka strain varicella-zoster virus [each dose contains not <103.3 plaque-forming units (PFU)]
Active immunisation against varicella of healthy subjects from 9 mth of age.
Dosage/Direction for Use
SC Adult, adolescent ≥13 yr & childn 9 mth to 12 yr 2 doses. Administer 2nd dose at least 6 wk after 1st dose.
Hypersensitivity to any component of the vaccine, to neomycin, or after previous administration of varicella vaccine. Subjects w/ primary or acquired immunodeficiency states w/ total lymphocyte count <1,200/mm3; presenting other evidence of lack of cellular immune competence; receiving immunosuppressive therapy including high dose of corticosteroids. Pregnancy (avoid 1 mth after vaccination).
Special Precautions
Postpone vaccination in subjects suffering from acute severe febrile illness. Alcohol & other disinfecting agents must be allowed to evaporate from the skin before inj of the vaccine. Cases of mild varicella disease. Transmission of the Oka vaccine. Immunocompromised subjects. Do not administer intravascularly or intradermally. Depression of tuberculin skin sensitivity.
Adverse Reactions
Pain, redness; swelling at inj site, fever (oral/axillary temp ≥37.5°C or rectal temp ≥38°C), rash.
Drug Interactions
Reports of Reye's syndrome w/ salicylates. Likelihood of vaccine failure w/ human gammaglobulins or blood transfusions. High-risk patients: Do not administer at the same time as other live attenuated vaccines.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BK01 - varicella, live attenuated ; Belongs to the class of varicella viral vaccines.
Varilrix vaccine (inj)
(vial) 0.5 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in